165 related articles for article (PubMed ID: 37409174)
1. Impact of the gating strategy for Ki-67 and Bcl-2 on the determination of proliferation and anti-apoptosis data by flow cytometry in non-malignant bone marrow aspirates and aspirates from patients with myeloid malignancies.
Mestrum SGC; Vanblarcum RBY; de Wit NCJ; Drent RJM; Boonen BT; van Hemert WLW; Hopman AHN; Ramaekers FCS; Leers MPG
Data Brief; 2023 Aug; 49():109284. PubMed ID: 37409174
[TBL] [Abstract][Full Text] [Related]
2. Optimized gating strategy and supporting flow cytometry data for the determination of the Ki-67 proliferation index in the diagnosis of myelodysplastic syndrome.
Mestrum SGC; Cremers EMP; de Wit NCJ; Drent RJM; Ramaekers FCS; Hopman AHN; Leers MPG
Data Brief; 2022 Apr; 41():107976. PubMed ID: 35252494
[TBL] [Abstract][Full Text] [Related]
3. MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.
Mestrum SGC; Roanalis BYV; de Wit NCJ; Drent RJM; Boonen BT; van Hemert WLW; Hopman AHN; Ramaekers FCS; Leers MPG
Leuk Res; 2024 Jul; 142():107520. PubMed ID: 38776565
[TBL] [Abstract][Full Text] [Related]
4. Proliferative and anti-apoptotic fractions in maturing hematopoietic cell lineages and their role in homeostasis of normal bone marrow.
Mestrum SGC; Vanblarcum RBY; Drent RJM; Boonen BT; van Hemert WLW; Ramaekers FCS; Hopman AHN; Leers MPG
Cytometry A; 2022 Jul; 101(7):552-563. PubMed ID: 35429122
[TBL] [Abstract][Full Text] [Related]
5. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
[TBL] [Abstract][Full Text] [Related]
6. Determination of the proliferative fractions in differentiating hematopoietic cell lineages of normal bone marrow.
Nies KPH; Kraaijvanger R; Lindelauf KHK; Drent RJMR; Rutten RMJ; Ramaekers FCS; Leers MPG
Cytometry A; 2018 Nov; 93(11):1097-1105. PubMed ID: 30176186
[TBL] [Abstract][Full Text] [Related]
7. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
8. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.
Parker JE; Fishlock KL; Mijovic A; Czepulkowski B; Pagliuca A; Mufti GJ
Br J Haematol; 1998 Dec; 103(4):1075-82. PubMed ID: 9886323
[TBL] [Abstract][Full Text] [Related]
9. The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.
Mestrum SGC; Hopman AHN; Ramaekers FCS; Leers MPG
Blood Adv; 2021 Apr; 5(7):2040-2052. PubMed ID: 33847740
[TBL] [Abstract][Full Text] [Related]
10. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Analysis of Hematopoietic Stem and Progenitor Cell Populations in Acute Myeloid Leukemia Based on Spectral Flow Cytometry, a 20-Color Panel, and Unsupervised Learning Algorithms.
Matthes T
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474094
[TBL] [Abstract][Full Text] [Related]
14. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
15. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
16. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
17. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
18. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
[TBL] [Abstract][Full Text] [Related]
19. Integration of the Ki-67 proliferation index into the Ogata score improves its diagnostic sensitivity for low-grade myelodysplastic syndromes.
Mestrum SGC; Cremers EMP; de Wit NCJ; Drent RJM; Ramaekers FCS; Hopman AHN; Leers MPG
Leuk Res; 2022 Feb; 113():106789. PubMed ID: 35101793
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
